ClinicalTrials.gg
TerminatedNCT01037101Updated Oct 22, 2026Results posted

D-Cycloserine-Enhancer of One-Session Treatment for Phobia of Heights

A Phase 2 interventional study of In Vivo Exposure Therapy and Virtual Reality Exposure Therapy in Height Phobia, sponsored by CAMC Health System. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by CAMC Health System · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Lack of enrollment, 5 completed by 2011 however no further enrollment took place until study terminated in 2017.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2009, registered Dec 2009).
Updated Oct 22, 2026Now TerminatedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The study will determine the effects of D-Cycloserine (DCS) on fear reduction in patients diagnosed with phobia of heights (acrophobia) undergoing one session of three hours of virtual reality exposure therapy (VRET) or in vivo exposure therapy (IVET).

Read the detailed description

The impact of D-Cycloserine on Virtual Reality Exposure Therapy (VRET) and In Vivo Exposure Therapy (IVET) for phobia of heights (acrophobia) will be tested using a randomized, double-blind, placebo-controlled trial. Eighty participants will be randomly assigned to one of the four treatment conditions: one-session VRET (3 hours) and 50 mg D-Cycloserine (VR-OST + DCS, N1=20); one-session VRET (3 hours) and placebo (VR-OST + Pl, N2=20); one-session IVET (3 hours) and placebo (IV + Pl, N3=20); or one-session IVET (3 hours) and 50 mg D-Cycloserine, (IV + DCS, N4=20). For twenty participants (5 from each group) the treatment will be delayed for three weeks and an additional assessment will be conducted as they will comprise a Wait List (WL) control group. Behavioral, cognitive and physiological changes in acrophobia will be assessed at pre-treatment, post-waitlist, post-treatment and 3 months follow-up.

02

Conditions studied

  • Height Phobia

Browse trials for

Keywords

  • acrophobia
  • virtual reality
  • exposure therapy
  • In Vivo Exposure Therapy plus D-Cycloserine
  • In Vivo Exposure Therapy plus Placebo
  • Virtual Reality Exposure Therapy plus D-Cycloserine
  • Virtual Reality Exposure Therapy plus Placebo
  • Wait-List
03

In context

Acrophobia

22 studies on the registry are indexed under Acrophobia; none are open to participants now.

This study's enrollment of 4 is below the median of 60 across 22 interventional studies indexed under Acrophobia.

Browse Acrophobia studies →

Lead sponsor

CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years
  • Men and women
  • Diagnosis of acrophobia based on a clinical interview (ADIS-IV)
  • Must sign an document after complete explanation of the study documenting that they understand the purpose of the study, procedures to be undertaken, possible benefits, potential risks, and are willing to participate.

Exclusion criteria

Exclusion Criteria:

  • A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders; organic brain syndrome, cognitive dysfunction that could interfere with capacity to engage in therapy;
  • A history of substance or alcohol dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol use during the period of study participation.
  • Patients with significant suicidal ideation or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate services.
  • Patients must be off concurrent anxiolytics and beta blockers and on a stable dose of antidepressant medication for at least 3 weeks prior to initiation of randomized treatment.
  • Patients receiving medication that might interfere with study medication (medication that might lower seizure threshold: meperidine or antibiotics in high dosage: penicillins, cephalosporins, amphotericin and imipenem),
  • Patients with a current or past history of seizures
  • Pregnant women, lactating women, and women of who are not using medically accepted effective methods of or abstinence
  • Patients with a history of renal insufficiency ( less than 60 mL/min) or liver insufficiency
  • Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration specifically targeting phobias
  • Patients unable to understand study procedures and participate in the process.
  • Other serious medical illnesses (e.g., cardiovascular, liver, kidney, respiratory, endocrine, neurologic, or blood-related diseases),
  • Inability to tolerate wearing the Virtual Reality Head Mounted Display,
  • If patients refuse the study medication
  • Any allergic reactions to D-Cycloserine by history
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Active comparator
    IVET+DCS

    Behavioral: In Vivo Exposure Therapy · Drug: D-Cycloserine

  • Experimental
    VRET+DCS

    Behavioral: Virtual Reality Exposure Therapy · Drug: D-Cycloserine

  • Experimental
    VRET+Placebo

    Behavioral: Virtual Reality Exposure Therapy · Drug: Placebo

  • Active comparator
    IVET+Placebo

    Behavioral: In Vivo Exposure Therapy · Drug: Placebo

Interventions

  • BehavioralIn Vivo Exposure Therapy

    Three hours of exposure therapy in a high place

  • BehavioralVirtual Reality Exposure Therapy

    Three hours of exposure therapy using a virtual reality system

  • DrugCycloserineStudies of CycloserineCycloserine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    50 mg of DCS administered 30 minutes before the session

    Also known as: Seromycin

  • DrugPlacebo

    50 mg placebo administered 30 minutes before the session

06

What researchers measure

Primary outcomes

  1. Specific Phobia (Acrophobia) Diagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)

    Presence or absence of a diagnosis of specific phobia (acrophobia) as assessed using the Anxiety Disorders Interview Schedule-IV (ADIS-IV).

    Time frame: One-week post-treatment and 3-months follow-up

Secondary outcomes

  1. Physiological Responses to Phobia-related Stimuli, Percentage of Steps Completed and Subjective Units of Distress During a Behavioral Avoidance Test (BAT)

    Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT) - Study was terminated due to lack of enrollment and outcome data are unavailable

    Time frame: One-week post-treatment and 3-months follow-up

  2. Number of Steps Completed During the Behavioral Analysis Test (BAT)

    Number of steps completed during exposure to the feared stimulus. Higher numbers will indicate greater completion of the BAT procedure at the assessment

    Time frame: One-week post-treatment and 3-months follow-up

  3. Subjective Units of Distress (SUDS) During BAT

    Participant-supported SUDS ratings to be obtained during BAT to assess distress associated with exposure to the feared stimulus

    Time frame: One-week post-treatment and 3-months follow-up

07

Results

Posted Oct 22, 2026

Participant flow

Patients will be either self referred based on ads posted in local newspapers or referred by their primary physician to the WVU Behavioral Medicine and Psychiatry Department (CAMC) for treatment of flying or height phobia. Upon referral, a brief phone screening interview assessing phobic status and relevant medical history will be conducted by the principal investigator

Participant flow — Overall Study
MilestoneIVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-List
Started11111
Completed11111
Not completed00000

Outcome measures

PrimarySpecific Phobia (Acrophobia) Diagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)

Presence or absence of a diagnosis of specific phobia (acrophobia) as assessed using the Anxiety Disorders Interview Schedule-IV (ADIS-IV).

Time frame:
One-week post-treatment and 3-months follow-up
Reported as:
Count of participants · Participants
Specific Phobia (Acrophobia) Diagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)
ParticipantsIVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-List
Specific Phobia (Acrophobia) Diagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)00000
SecondaryPhysiological Responses to Phobia-related Stimuli, Percentage of Steps Completed and Subjective Units of Distress During a Behavioral Avoidance Test (BAT)

Physiological responses to phobia-related stimuli, percentage of steps completed and Subjective Units of Distress during a Behavioral Avoidance Test (BAT) - Study was terminated due to lack of enrollment and outcome data are unavailable

Time frame:
One-week post-treatment and 3-months follow-up
Reported as:
Count of participants · Participants
Physiological Responses to Phobia-related Stimuli, Percentage of Steps Completed and Subjective Units of Distress During a Behavioral Avoidance Test (BAT)
ParticipantsIVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-List
Physiological Responses to Phobia-related Stimuli, Percentage of Steps Completed and Subjective Units of Distress During a Behavioral Avoidance Test (BAT)00000
SecondaryNumber of Steps Completed During the Behavioral Analysis Test (BAT)

Number of steps completed during exposure to the feared stimulus. Higher numbers will indicate greater completion of the BAT procedure at the assessment

Time frame:
One-week post-treatment and 3-months follow-up
Reported as:
Count of participants · Participants
Number of Steps Completed During the Behavioral Analysis Test (BAT)
ParticipantsIVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-List
Number of Steps Completed During the Behavioral Analysis Test (BAT)00000
SecondarySubjective Units of Distress (SUDS) During BAT

Participant-supported SUDS ratings to be obtained during BAT to assess distress associated with exposure to the feared stimulus

Time frame:
One-week post-treatment and 3-months follow-up
Reported as:
Count of participants · Participants
Subjective Units of Distress (SUDS) During BAT
ParticipantsIVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-List
Subjective Units of Distress (SUDS) During BAT00000

Adverse events

Collected over One-week post-treatment and 3 months follow-up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IVET+DCS———
VRET+DCS———
VRET+Placebo———
IVET+Placebo———
Wait-List———

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)IVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-ListTotal
<=18 years000000
Between 18 and 65 years000000
>=65 years000000
Sex: Female, Male
Sex: Female, Male(Participants)IVET+DCSVRET+DCSVRET+PlaceboIVET+PlaceboWait-ListTotal
Female000000
Male000000
08

Study locations

1 site
  • West Virginia University School of Medicine Charleston Division
    Charleston, West Virginia 25304, United States
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2009 to primary completion in Feb 2012, 31 months.

Results were first posted in Oct 2026, 14 years 8 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Dec 2014 → Feb 2012 and completion Dec 2014 → Jun 2017.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2009
First posted
Dec 21, 2009
StartActual
Jul 10, 2009
Primary completionActual
Feb 21, 2012was Dec 2014
CompletionActual
Jun 27, 2017was Dec 2014
Results first posted
Oct 22, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated Lack of enrollment, 5 completed by 2011 however no further enrollment took place until study terminated in 2017.
changed Oct 22, 2026
Results
Results posted
posted Oct 22, 2026
Primary completion
Dec 2014→Feb 21, 2012 (actual)
Oct 22, 2026
Study completion
Dec 2014→Jun 27, 2017 (actual)
Oct 22, 2026
Enrollment
80 (estimated)→4 (actual)
Oct 22, 2026
Interventions
Arms removed: Wait-List
Oct 22, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedSpecific Phobia (acrophobiaAcrophobia) diagnosis basedDiagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)Time frame: One week post-treatment and 3 months folow-up → One-week post-treatment and 3-months follow-up
Oct 22, 2026
Secondary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedPhysiological responsesResponses to phobiaPhobia-related stimuliStimuli, percentagePercentage of steps completedSteps Completed and Subjective Units of Distress duringDuring a Behavioral Avoidance Test (BAT)Time frame: One week post-treatment and 3 months follow-up → One-week post-treatment and 3-months follow-up
  • AddedNumber of Steps Completed During the Behavioral Analysis Test (BAT)Time frame: One-week post-treatment and 3-months follow-up
  • AddedSubjective Units of Distress (SUDS) During BATTime frame: One-week post-treatment and 3-months follow-up
Oct 22, 2026
Design
Not applicable→Phase 2
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Status unknown→Terminated
    Why stopped Lack of enrollment, 5 completed by 2011 however no further enrollment took place until study terminated in 2017.
    Results posted
    Primary completion Dec 2014→Feb 21, 2012 (now actual)
    Study completion Dec 2014→Jun 27, 2017 (now actual)
    Enrollment 80 (estimated)→4 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedSpecific Phobia (acrophobiaAcrophobia) diagnosis basedDiagnosed Based on Anxiety Disorders Interview Schedule - IV (ADIS-IV)Time frame: One week post-treatment and 3 months folow-up → One-week post-treatment and 3-months follow-up
    Secondary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedPhysiological responsesResponses to phobiaPhobia-related stimuliStimuli, percentagePercentage of steps completedSteps Completed and Subjective Units of Distress duringDuring a Behavioral Avoidance Test (BAT)Time frame: One week post-treatment and 3 months follow-up → One-week post-treatment and 3-months follow-up
    • AddedNumber of Steps Completed During the Behavioral Analysis Test (BAT)Time frame: One-week post-treatment and 3-months follow-up
    • AddedSubjective Units of Distress (SUDS) During BATTime frame: One-week post-treatment and 3-months follow-up
    Interventions Arms removed: Wait-List
    Design Not applicable→Phase 2
    + 5 other changes: verification date, responsible party, site details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01037101
Lead sponsor
CAMC Health System
Collaborators
West Virginia University, University of Charleston
Responsible party
Sponsor
First posted
Dec 21, 2009
Start date
Jul 10, 2009
Primary completion
Feb 21, 2012
Completion
Jun 27, 2017
Results posted
Oct 22, 2026
Last update
Oct 22, 2026

Study contacts

Cristian Sirbu, Ph.D.
principal investigator · CAMC Health System

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cycloserine

Start the discussion